KUALA LUMPUR, 18 December 2020 – HWGB Biotech Sdn Bhd (“HWGB Biotech”), a wholly owned subsidiary of Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601), today signed a Memorandum of Understanding (“MoU”) with Nihao Global Corporation Limited (“Nihao Global”) to promote HWGB Group's medical related devices and products. Through the collaboration, Nihao Global will review and assess the applicable medical devices and products for approval to be listed on their medical products HUB (the “HUB”) www.medicalproductshub.com upon successful accreditation and approval received from the World Health Organization (“WHO”). For information purposes, WHO had joined the HUB since 23 October 2020.
Please refer to https://mp.weixin.qq.com/s/V4_SMe0rgF7DSCsRnMZe3A
Nihao Global is a company incorporated and based in Hong Kong. Nihao Global provides personalised and specialised services to business that requires initiation and maintaining the traction within the Chinese market place. It has subsidiaries in Australia (Nihao Global Corporation Pty Ltd) and Mainland China (Beijing Nihao Advisory). Through the HUB, an established one-stop digital medical product distribution marketplace that provides an end-to-end solution for buyers to purchase bulk medical supplies and equipment at wholesale rates, HWGB Biotech is able to market its medical related devices and products globally, including Asia, America and European countries. Moreover, the HUB is also supported by a number of Government Agencies for the supply of medical devices and products, which consists of eleven categories of certified products.
Chief Executive Officer of HWGB, Dato’ Aaron Lim said: “Good and reliable COVID-19 medical devices and products are needed especially with the daily rise in the number of cases globally. Following the announcement made on our digital expansion plan on 20 Nov 2020, Nihao Global is one of the channel that help in facilitating the distribution of these medical devices and products. After WHO expedites our medical device and product’s registration, we can start distributing it soon to global market".
Chairman of Nihao Global, Mr.Nigel Blair, said: “We welcome the opportunity to work with HWGB Biotech as we are always looking to expand our network of reliable partners and suppliers. We can deliver medical products throughout the globe in volume at a fair price as we have the relationship with suppliers as well as the ability to leverage on the global logistics chain".
HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the distribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
For more information on about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn and Telegram to view the latest updates about our company ventures in the healthcare industry.
World Health Organization had joined the HUB since 23 October 2020. Please refer to the website below for more information: https://mp.weixin.qq.com/s/V4_SMe0rgF7DSCsRnMZe3A
Nihao Global (“Nihao” or the “Company”) is a unique independent service company where East meets West. Not only are their management have a mix of Eastern and Western style, so do their systems, thinking and operations. The Company combines the best of both East and West service standards to deliver a seamless service. Nihao provides skilled consulting & bilingual human resources to work effectively within China’s unique business environment.
2020 HWGB Biotech. All rights Reserved.